1969
DOI: 10.1126/science.165.3896.875
|View full text |Cite
|
Sign up to set email alerts
|

FDA and Panalba: A Conflict of Commercial, Therapeutic Goals?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
15
0

Year Published

1975
1975
2014
2014

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 20 publications
(15 citation statements)
references
References 0 publications
0
15
0
Order By: Relevance
“…Consider, for example, the ''Panalba'' case, involving the pharmaceutical company Upjohn. After strong medical evidence emerged that the drug was causing a number of serious side-effects (including unnecessary deaths) and that it offered no medical benefits beyond those that could be obtained from other products on the market, the board of directors of the firm decided not only to continue marketing and selling the drug, but also arranged to have a judge issue an injunction to stop the FDA from taking regulatory action (Mintz, 1969). When the FDA finally succeeded in having the drug banned in the United States, the firm continued to sell it in foreign markets.…”
Section: Charactermentioning
confidence: 99%
“…Consider, for example, the ''Panalba'' case, involving the pharmaceutical company Upjohn. After strong medical evidence emerged that the drug was causing a number of serious side-effects (including unnecessary deaths) and that it offered no medical benefits beyond those that could be obtained from other products on the market, the board of directors of the firm decided not only to continue marketing and selling the drug, but also arranged to have a judge issue an injunction to stop the FDA from taking regulatory action (Mintz, 1969). When the FDA finally succeeded in having the drug banned in the United States, the firm continued to sell it in foreign markets.…”
Section: Charactermentioning
confidence: 99%
“…The accountability portion of the study consisted of an ethical decision scenario in which subjects were asked to role play a member of a board of directors and make a decision concerning the marketing of a product. The Panalba decision task entailed making a group decision based on the facts of a case that arose between the Upjohn Corporation and the Food and Drug Administration (FDA) in 1969 (see Mintz, 1969). In the decision task, however, Upjohn was not mentioned by name thereby reducing potential identification of the actual incident.…”
Section: Measurementmentioning
confidence: 99%
“…This was the decision that had been made by Upjohn. According to Mintz [45], Upjohn had a judge serve an injunction on the FDA, and they also used political pressure. Although Upjohn was eventually forced to remove Panalba from the U.S. market in March 1970, it continued to sell Panalba in foreign markets [46].…”
Section: Administration Of the Experimentmentioning
confidence: 99%